1. PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
- Author
-
Hideto Tamura, Mariko Ishibashi, Mika Sunakawa-Kii, and Koiti Inokuchi
- Subjects
0301 basic medicine ,Cancer Research ,monoclonal gammopathy of undetermined significance (MGUS) ,Review ,lcsh:RC254-282 ,Asymptomatic ,immune checkpoint inhibitors ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,Refractory ,PD-L1 (B7-H1) ,PD-L1 ,hemic and lymphatic diseases ,PD-1 ,medicine ,PI3K/AKT/mTOR pathway ,Multiple myeloma ,biology ,business.industry ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Pathophysiology ,multiple myeloma ,030104 developmental biology ,AKT pathway ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,medicine.symptom ,business ,Monoclonal gammopathy of undetermined significance - Abstract
PD-L1 expressed on tumor cells contributes to disease progression with evasion from tumor immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD-L1 compared with healthy volunteers and monoclonal gammopathy of undetermined significance (MGUS) patients, and its expression is significantly upregulated in relapsed/refractory patients. Furthermore, high PD-L1 expression is induced by the myeloma microenvironment and PD-L1+ patients with MGUS and asymptomatic MM tend to show disease progression. PD-L1 expression on myeloma cells was associated with more proliferative potential and resistance to antimyeloma agents because of activation of the Akt pathway through PD-1-bound PD-L1 in MM cells. Those data suggest that PD-L1 plays a crucial role in the disease progression of MM.
- Published
- 2020